Manuel Ginarte and Jaime Toribio

*Department of Dermatology. Complejo Hospitalario Universitario de Santiago. Faculty of Medicine. Santiago de Compostela, Spain* 

### **1. Introduction**

118 Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights

Sanders, D. B. (2004). Electrophysiologic tests of neuromuscular transmission. *Suppl Clin* 

Sanders, D. B. and Evoli, A. (2010). Immunosuppressive therapies in myasthenia gravis.

Sanders, D. B. and Stalberg, E. V. (1996). AAEM minimonograph #25: single-fiber

Schumm, F., Wiethölter, H., Fateh-Moghadam, A. and Dichgans, J. (1985). Thymectomy in myasthenia with pure ocular symptoms. *J Neurol Neurosurg Psychiatry* 48: pp. 332-337. Seybold, M. E. (1999). Diagnosis of myasthenia gravis. Myasthenia gravis and myasthenic disorders. A. G. Engel. New York, Oxford University Press: 146-166. Sieb, J. P. and Kohler, W. (2010). Benefits from sustained-release pyridostigmine bromide in

Sommer, N., Melms, A., Weller, M. and Dichgans, J. (1993). Ocular myasthenia gravis, a critical review of clinical and pathophysiological aspects. *Doc Ophthalmol* 84: pp. 309-333. Sommer, N., Sigg, B., Melms, A., Weller, M., Schepelmann, K., Herzau, V. and Dichgans, J.

Somnier, F., Keiding, N. and Paulson, O. (1991). Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive study. *Arch Neurol* 48: pp. 733-739. Srivastava, A., Kalita, J. and Misra, U. K. (2007). A comparative study of single fiber

Tackenberg, B., Hemmer, B., Oertel, W. H. and Sommer, N. (2001). Immunosuppressive

Tsiptsios, D., Fotiou, D. F., Haidich, A. B., Brozou, G. C., Nakou, M., Giantselidis, C.,

Verschuuren, J. J., Palace, J. and Gilhus, N. E. (2010). Clinical aspects of myasthenia

Vincent, A., Bowen, J., Newsom-Davis, J. and McConville, J. (2003). Seronegative

Vincent, A., Clover, L., Buckley, C., Grimley Evans, J. and Rothwell, P. M. (2003). Evidence

Vincent, A., Palace, J. and Hilton-Jones, D. (2001). Myasthenia gravis. *Lancet* 357(9274): pp.

Wong, V., Hawkins, B. R. and Yu, Y. L. (1992). Myasthenia gravis in Hong Kong Chinese.

Zhou, L., McConville, J., Chaudhry, V., Adams, R. N., Skolasky, R. L., Vincent, A. and Drachman,

positive and -negative myasthenic patients. *Muscle Nerve* 30(1): pp. 55-60.

myasthenia gravis. *Electromyogr Clin Neurophysiol* 47(2): pp. 93-96.

myasthenia gravis. *Electromyogr Clin Neurophysiol* 48(5): pp. 209-218. Ukachoke, C., Ashby, P., Basinski, A. and Sharpe, J. A. (1994). Usefulness of single fiber

myasthenia gravis: results of a prospective multicenter open-label trial. *Clin Neurol* 

(1997). Ocular myasthenia gravis: response to long term immunosuppressive

electromyography and repetitive nerve stimulation in consecutive patients with

Karlovasitou, A. and Fotiou, F. (2008). Evaluation of pupil mobility in patients with

EMG for distinguishing neuromuscular from other causes of ocular muscle

generalised myasthenia gravis: clinical features, antibodies, and their targets. *Lancet* 

of underdiagnosis of myasthenia gravis in older people. *J Neurol Neurosurg* 

D. B. (2004). Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-

*Neurophysiol* 57: pp. 167-169.

*Neurosurg* 112(9): pp. 781-784.

treatment of ocular myasthenia gravis.

weakness. *Can J Neurol Sci* 21(2): pp. 125-128.

explained. *Autoimmunity* 43(5-6): pp. 344-352.

*Neurol* 2(2): pp. 99-106.

2122-2128.

*Psychiatry* 74(8): pp. 1105-1108.

*Acta Neurol Scand* 86: pp. 68-72.

*Autoimmunity* 43(5-6): pp. 428-435.

electromyography. *Muscle Nerve* 19(9): pp. 1069-1083.

treatment. *J Neurol Neurosurg Psychiatry* 62: pp. 156-162.

Sweet syndrome (SS) was first described by Robert Sweet in 1964 as acute febrile neutrophilic dermatosis (Sweet, 1966). Despite of the descriptive value of this denomination and the advice of Robert Sweet to keep it, the eponymous became prevalent on the time. SS was the first neutrofilic dermatosis (ND) described and it represents the paradigm of them. There are three key points of SS that are of interest not only for the dermatologists but also for the general practitioners: a) its marked clinical manifestations, b) the potential systemic repercussion of neutrophilic reaction, and c) its association with extracutaneos diseases, especially with malignancies.
